PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Bibliographic Details
Published in:	HemaSphere
Main Authors:	S. Delimpasi, H. Quach, M. Cavo, P. J. Ho, C. H.-S. Lee, A. Santoro, R. Schots, P. Vlummens, D. H. Yoon, S.-S. Yoon, C. D. Santos, D. Samineni, J. Huang, K. Wehrman, U. Patil, S. Sheikh, M. A. Dimopoulos
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850972.76878.85

Similar Items

PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: R. Vij, et al.
Published: (2022-06-01)

P34 | CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: BIOMARKER ANALYSES FROM CAMMA 1 ARM B
by: R. Popat, et al.
Published: (2026-04-01)

Pityriasis lichenoides et varioliformis acuta in a patient treated with cevostamab
by: Jeremy Orloff, BA, et al.
Published: (2024-05-01)

CAMMA-RAY SPECTRUM OF BOVINE THYROID DURING UNCLEAR FALLOUT
by: HASSAN ASKARI SHIRAZI
Published: (1985-12-01)

Camma (Hide or Leather) in Theravāda-Vinaya: The Tension Between Permission and Prohibition
by: Jarang Lee
Published: (2025-06-01)

Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease
by: Ewa Papuć, et al.
Published: (2019-03-01)

La composizione di ‘Camma’ nel carteggio tra Adelaide Ristori, Giuseppe Montanelli e Lauretta Cipriani Parra
by: Giacomo Della Ferrera
Published: (2024-12-01)

An instance of excellent response of subcutaneous zygomycosis to itraconazole monotherapy
by: Priyadarshini Patro, et al.
Published: (2019-06-01)

Chiomara, Camma, et autres princesses… Une histoire des femmes dans les sociétés « celtiques » est‑elle possible ?
by: Sandra Péré-Noguès
Published: (2013-01-01)

A multi-center, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
by: Hang Quach, et al.
Published: (2024-08-01)

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
by: Maria-Victoria Mateos, et al.
Published: (2023-08-01)

Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma
by: Balaji Jothishankar, MD, et al.
Published: (2020-12-01)

Development of urbanized areas in Ukraine and the world for the period 1950–2035
by: L.V., et al.
Published: (2023-09-01)

Labor Market for Elderly People 2035
by: Annette Scoppetta
Published: (2008-09-01)

Making reproducibility a reality by 2035?
by: Rebecca Taylor-Grant, et al.
Published: (2025-05-01)

Content Marketing Futures in México, 2035
by: Eduardo Navarrete Pedraza
Published: (2025-05-01)

Российская Арктика-2035: полимасштабный прогноз
by: Александр Николаевич Пилясов, et al.
Published: (2024-06-01)

Educational virtual field trips 2035
by: Eisenlauer Volker, et al.
Published: (2026-04-01)

C002 | SUBCUTANEOUS DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NDMM: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN THE PHASE 3 PERSEUS TRIAL
by: E. Antonioli, et al.
Published: (2025-09-01)

P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE
by: P. Sonneveld, et al.
Published: (2026-04-01)

P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB
by: R. Nakamura, et al.
Published: (2022-06-01)

Optical Color of Type Ib and Ic Supernovae and Implications for Their Progenitors
by: Harim Jin, et al.
Published: (2023-01-01)

An Overview of the Further Demographic Situation and Economy in 2035
by: Олександр Грiбiнча
Published: (2018-12-01)

Circular Futures: Navigating the Built Environment of 2035
by: Patrick Moloney, et al.
Published: (2025-05-01)

Development Strategy of Smart Agriculture for 2035 in China
by: Zhao Chunjiang, et al.
Published: (2021-12-01)

“Rotterdam Waterstad 2035”: reagire alle perturbazioni
by: Silvia Mantovani
Published: (2015-11-01)

Salud global 2035: implicaciones para México
by: Naomi Beyeler, et al.
Published: (2015-09-01)

Trends in cigarette consumption across the United States, with projections to 2035.
by: Eric C Leas, et al.
Published: (2023-01-01)

Associated symptoms in patients with IBS
by: O. V. Taschyan, et al.
Published: (2015-12-01)

Subcutaneous Leiomyosarcoma of the Frenulum
by: D. Mendis, et al.
Published: (2005-01-01)

Technology foresight for the South African road transport sector by 2035
by: Frederik C. Rust, et al.
Published: (2024-08-01)

The labor potential reproduction in depopulation period of 2019–2035 and the compensating role of migration
by: A. V. Topilin, et al.
Published: (2019-11-01)

P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY
by: E Terpos, et al.
Published: (2022-04-01)

Symmetric equations on the surface of a sphere as used by model GISS:IB
by: G. L. Russell, et al.
Published: (2018-11-01)

Comment on “Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma”
by: Simon J. Harrison, et al.
Published: (2015-09-01)

Process of Ageing of Śląskie Voivodship Population Until 2035
by: Sojka Elżbieta
Published: (2011-01-01)

The Technological Impact on Employment in Spain between 2023 and 2035
by: Oussama Chemlal, et al.
Published: (2024-04-01)

China’s Energy Development for 2035: Strategic Thinking and Suggestions
by: Xie Kechang
Published: (2022-12-01)

„Strategie der Optimierung bis zum Jahr 2035“
by: Peter Stegmaier
Published: (2023-04-01)

Cariprazine as monotherapy in a case of First Episode of Psychosis (FEP)
by: P. Nasiou, et al.
Published: (2024-04-01)